TScan Therapeutics shares jumped 23% in premarket trading after a $30 million registered direct offering. Shares were trading around $3.58. The stock is down about 50% on the year.

Clinical-stage biotechnology company TScan Therapeutics, Inc. (TCRX) Thursday announced that it has entered into a securities ...

TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027 ...

Additional information about the reverse stock split can be found in Optinose's Definitive Proxy Statement filed with the Securities and Exchange Commission ("SEC”) on December 12, 2024. The Proxy ...

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for ...

TScan Therapeutics (TCRX) entered into a securities purchase agreement with Lynx1 Capital Management and an investment fund advised by Lynx1 for the sale of approximately $30M of pre-funded warrants ...

Key Insights Significantly high institutional ownership implies TScan Therapeutics' stock price is sensitive to ...

TScan Therapeutics, a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, announced ...

Gordon Brothers in a joint venture with Hilco Consumer - Retail and Tiger Capital Group, began store closing sales at all 869 Big Lots locations. The U.S. closeout retailer is offering up to 25% off ...

Wedbush reissued their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research report sent to investors on Monday morning,RTT News reports. The firm currently has a ...

The DIH Center of Excellence program recognizes strategic partners that showcase best practices in rehabilitation robotics ...